Chemistry:ASP-4345
ASP-4345, or ASP4345, is a dopamine D1 receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.[1][2][3][4] It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia.[1] The drug is taken orally.[1][5][4]
The most common side effects of ASP-4345 have been found to be headache and somnolence.[5] No changes in mood or suicidality were observed.[5] The pharmacokinetics of ASP-4345 have been studied.[4] The median time to peak levels of ASP-4345 is 1.0 to 3.0 hours.[4] Its mean elimination half-life is 9.1 to 26.8 hours.[4]
ASP-4345 is or was under development by Astellas Pharma.[1][2] As of March 2021, no recent development has been reported.[1] The drug has reached phase 2 clinical trials for schizophrenia.[1][2] It was found to be ineffective in a phase 2 trial.[3]
See also
- List of investigational antipsychotics
- Mevidalen (LY-3154207)
- Glovadalen (UCB-0022)
- DETQ
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "ASP 4345". 9 March 2021. https://adisinsight.springer.com/drugs/800042764.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on ASP-4345 with Synapse". 15 November 2025. https://synapse.patsnap.com/drug/fa6a6bd7502244938571196e062d14d5.
- ↑ 3.0 3.1 "Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments". International Journal of Molecular Sciences 22 (18): 9905. September 2021. doi:10.3390/ijms22189905. PMID 34576069.
- ↑ 4.0 4.1 4.2 4.3 4.4 "Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies". Clinical Pharmacokinetics 60 (1): 79–88. January 2021. doi:10.1007/s40262-020-00911-0. PMID 32533536.
- ↑ 5.0 5.1 5.2 "Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia". Neuropsychopharmacology 46 (6): 1145–1151. May 2021. doi:10.1038/s41386-020-00908-0. PMID 33203954.
 |  |
